Studies have shown that targeting the CXCL3-CXCR2 signaling pathway to restore IRF2 expression or therapeutically inhibit MDSCs can increase CRC sensitivity to immune checkpoint blockade (ICB) therapy [19]. Here, CXCL3 is linked to colorectal carcinoma.